Javascript is not enabled.

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.

A Sense of Déjà Vu: The Debate Surrounding State Biosimilar Substituti... Skip to content

From travel insurance to fraud protection, AARP has you covered. Take a closer look at your member benefits.

 

 

A Sense of Déjà Vu: The Debate Surrounding State Biosimilar Substitution Laws

The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics. This Insight on the Issues discusses controversial new state legislation that could greatly limit the savings from biosimilars and notes similarities to the debate ignited by the passage of federal legislation that encouraged the development of traditional generic drugs.

Read This Report

Join the Discussion

0 | Add Yours

Please leave your comment below.

You must be logged in to leave a comment.

GO TO THIS ARTICLE